What is RYBREVANT®
RYBREVANT® is a targeted antibody, which is a different kind of treatment from immunotherapy, chemotherapy, and TKIs
Clinical Benefits of RYBREVANT® + Chemotherapy
In a clinical trial, 308 people with advanced NSCLC with EGFR exon 20 insertion mutations received RYBREVANT® (amivantamab-vmjw) in combination with chemotherapy (carboplatin and pemetrexed) as a first treatment, or received chemotherapy alone as a first treatment.
RYBREVANT® + chemotherapy was studied in a varied population of adults who had EGFR exon 20 insertion mutations:
58% female
42% male
61% Asian
36% White
58% never smoked
42% current or former smokers
RYBREVANT® in combination with chemotherapy extended the time people lived without cancer growing or spreading
Almost twice the time without disease progression
At 11.4 months, half of the people treated with RYBREVANT® + chemotherapy lived without the disease getting worse, compared with 6.7 months for chemotherapy alone.
RYBREVANT® (amivantamab-vmjw) + chemotherapy improved response rates
of people responded to RYBREVANT® + chemotherapy compared with 36% of people on chemotherapy alone.
4% of people no longer had detectable* cancer compared with 1% of people on chemotherapy alone.
63% of people saw partial tumor shrinkage† compared with 36% of people on chemotherapy alone.
*A complete response: tumor no longer detectable; however this does not necessarily mean the cancer has been cured.
†A partial response: measurable tumor shrinkage but still detectable.
Clinical Benefits of RYBREVANT® Alone
In a clinical trial, RYBREVANT® was studied in 81 people who had mNSCLC with EGFR exon 20 insertion mutations whose disease had worsened while on or after chemotherapy that contains platinum
- Most people in the trial were women (59%)
- Over half never smoked (53%)
- The main goal of the trial was to measure the number of people who responded to RYBREVANT® overall
40% of people treated with RYBREVANT® after chemotherapy that contains platinum saw their tumors disappear* (3.7%) or get smaller (36%).
*The disappearance of all signs of cancer in response to treatment does not always mean the cancer has been cured.
The median response time for people treated with RYBREVANT® was 11.1 months.
- This means half of people responded to RYBREVANT® for 11.1 months or longer, and half responded for less than 11.1 months
- 63% of people responded to RYBREVANT® for 6 months or longer
It’s important to know what to expect while on treatment with RYBREVANT®
EGFR, epidermal growth factor receptor; mNSCLC, metastatic non–small cell lung cancer; TKI, tyrosine kinase inhibitor.
Side Effects With RYBREVANT®
You may experience some side effects while on treatment with RYBREVANT®
There can be common and serious side effects that happen while on treatment. Keep your care team informed about how you’re feeling. They can help you manage side effects when starting—or during—treatment.
Possible serious side effects of RYBREVANT®:
Infusion-related reactions. Infusion-related reactions are common with RYBREVANT® and can be severe or serious. Tell your healthcare provider right away if you get any of the following symptoms during your infusion of RYBREVANT®: shortness of breath, fever, chills, nausea, flushing, chest discomfort, lightheadedness, or vomiting.
Lung problems. RYBREVANT® may cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.
Skin problems. RYBREVANT® may cause rash, itching, and dry skin. You may use alcohol-free moisturizing cream for dry skin. Tell your healthcare provider right away if you get any skin reactions. Your healthcare provider may treat you with a medicine(s) or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment with RYBREVANT®. You should limit your time in the sun during and for 2 months after your treatment with RYBREVANT®. Wear protective clothing and use sunscreen during treatment with RYBREVANT®.
Eye problems. RYBREVANT® may cause eye problems. Tell your healthcare provider right away if you get symptoms of eye problems which may include: eye pain, dry eyes, eye redness, blurred vision, changes in vision, itchy eyes, excessive tearing, or sensitivity to light. Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get eye problems during treatment with RYBREVANT®. You should not use contact lenses until your eye symptoms are checked by a healthcare provider.
The most common side effects of RYBREVANT® in combination with chemotherapy
include:
- rash
- infected skin around the nail
- sores in the mouth
- infusion-related reactions
- feeling very tired
- swelling of hands, ankles, feet, face, or all of your body
- constipation
- decreased appetite
- nausea
- COVID-19
- diarrhea
- vomiting
- changes in certain blood tests
11% of people stopped treatment with RYBREVANT® because of side effects. 64% of people had their treatment interrupted due to side effects. 38% of people had their infusion interrupted because of an infusion-related reaction (IRR). 36% of people had their dose reduced due to side effects.
These side effects were seen in a clinical study of RYBREVANT® in combination with chemotherapy. Your experience and risk may vary.
The most common side effects of RYBREVANT® when given alone include:
- rash
- infusion-related reactions
- infected skin around the nail
- muscle and joint pain
- shortness of breath
- nausea
- feeling very tired
- swelling of hands, ankles, feet, face, or all of your body
- sores in the mouth
- cough
- constipation
- vomiting
- changes in certain blood tests
11% of people stopped treatment with RYBREVANT® because of side effects. 78% of people had their treatment interrupted due to side effects. 59% of people had their infusion interrupted because of an infusion-related reaction (IRR). 15% of people had their dose reduced due to side effects
These side effects were seen in a clinical study of RYBREVANT®. Your experience and risk may vary.
What you should know about infusion-related reactions (IRRs)
Your care team is trained to help you with any IRRs you may experience, so make sure to tell them how you’re feeling during your infusion. Here are some things you should know about IRRs:
IRRs are common with RYBREVANT® and can be severe or serious
IRRs can involve shortness of breath, fever, chills, nausea, flushing, chest discomfort, lightheadedness, or vomiting that occur during your infusion
IRRs were one of the most common side effects in clinical trials. IRRs occurred in 66% of people treated with RYBREVANT® alone and 42% of people treated with RYBREVANT® in combination with carboplatin and pemetrexed
Your healthcare provider will give you medicines before each dose of RYBREVANT® to help reduce the risk of these reactions
Pay close attention to how you feel during an infusion, and make sure to let your care team know if you experience any discomfort—they know how to help.
Find out how RYBREVANT® targets EGFR exon 20 insertion mutations in mNSCLC
How RYBREVANT® Works
RYBREVANT® is the only treatment of its kind designed to target mNSCLC with EGFR exon 20 insertion mutations
RYBREVANT® is a targeted antibody that:
- Directly blocks EGFR on the outside of the cell to stop tumors from growing
- Works with your body's immune system to identify and destroy cancer cells with EGFR
Register for Updates
Sign up to receive the latest news and information about RYBREVANT®
